ORBi: Munaut Carine - Differential expression of Vegfr-2 and its soluble form in preeclampsia.

Reference : Differential expression of Vegfr-2 and its soluble form in preeclampsia.


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
	To cite this reference:	http://hdl.handle.net/2268/124720

Title :	Differential expression of Vegfr-2 and its soluble form in preeclampsia.
Language :	English
Author, co-author :	Munaut, Carine [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
	LORQUET, Sophie [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique CHR >]
	Pequeux, Christel [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
	Coulon, C [ > > ]
	Le Goarant, J [ > > ]
	CHANTRAINE, Frédéric [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique CHR >]
	Noël, Agnès [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
	GOFFIN, Frédéric [Centre Hospitalier Universitaire de Liège - CHU > > Gynécologie-Obstétrique CHR >]
	Tsatsaris, V [ > > ]
	Subtil, D [ > > ]
	Foidart, Jean-Michel [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique >]
Publication date :	Mar-2012
Journal title :	PLoS ONE
Publisher :	Public Library of Science
Volume :	7
Issue/season :	3
Pages :	e33475
Audience :	International
e-ISSN :	1932-6203
City :	San Franscisco
Country :	CA
Abstract :	[en] Background: Several studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial dysfunction related to excess circulating anti-angiogenic factors, most notably, soluble sVEGFR-1 (also known as sFlt-1) and soluble endoglin (sEng), as well as to decreased PlGF. Recently, soluble VEGF type 2 receptor (sVEGFR-2) has emerged as a crucial regulator of lymphangiogenesis. To date, however, there is a paucity of information on the changes of VEGFR-2 that occur during the clinical onset of PE. Therefore, the aim of our study was to characterize the plasma levels of VEGFR-2 in PE patients and to perform VEGFR-2 immunolocalization in placenta. METHODOLOGY/PRINCIPAL FINDINGS: By ELISA, we observed that the VEGFR-2 plasma levels were reduced during PE compared with normal gestational age matched pregnancies, whereas the VEGFR-1 and Eng plasma levels were increased. The dramatic drop in the VEGFR-1 levels shortly after delivery confirmed its placental origin. In contrast, the plasma levels of Eng and VEGFR-2 decreased only moderately during the early postpartum period. An RT-PCR analysis showed that the relative levels of VEGFR-1, sVEGFR-1 and Eng mRNA were increased in the placentas of women with severe PE. The relative levels of VEGFR-2 mRNA as well as expressing cells, were similar in both groups. We also made the novel finding that a recently described alternatively spliced VEGFR-2 mRNA variant was present at lower relative levels in the preeclamptic placentas. CONCLUSIONS/SIGNIFICANCE: Our results indicate that the plasma levels of anti-angiogenic factors, particularly VEGFR-1 and VEGFR-2, behave in different ways after delivery. The rapid decrease in plasma VEGFR-1 levels appears to be a consequence of the delivery of the placenta. The persistent circulating levels of VEGFR-2 suggest a maternal endothelial origin of this peptide. The decreased VEGFR-2 plasma levels in preeclamptic women may serve as a marker of endothelial dysfunction.
Permalink :	http://hdl.handle.net/2268/124720
DOI :	10.1371/journal.pone.0033475

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	Munaut C Plos one 2012.pdf		Publisher postprint	488.08 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5